NeoGenomics, Inc. Restructuring Costs and Asset Impairment Charges
NeoGenomics, Inc. (NEO) reported Restructuring Costs and Asset Impairment Charges of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-04-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2025-04-29
- NeoGenomics, Inc. restructuring costs and asset impairment charges for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. restructuring costs and asset impairment charges for the quarter ending 2024-12-31 was $1.71M, a 41.66% increase year-over-year.
- NeoGenomics, Inc. restructuring costs and asset impairment charges for the quarter ending 2024-09-30 was $1.01M, a 52.52% decline year-over-year.
- NeoGenomics, Inc. restructuring costs and asset impairment charges for the quarter ending 2024-06-30 was $1.54M, a 49.77% decline year-over-year.
- NeoGenomics, Inc. restructuring costs and asset impairment charges for fiscal 2024 was $6.66M, a 39.95% decline from fiscal 2023.
- NeoGenomics, Inc. restructuring costs and asset impairment charges for fiscal 2023 was $11.09M, a 145.53% increase from fiscal 2022.
- NeoGenomics, Inc. restructuring costs and asset impairment charges for fiscal 2022 was $4.52M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | $1.71M derived: sum of 2 quarters · filed 2025-04-29 | $2.72M derived: sum of 3 quarters · filed 2025-04-29 | $4.26M derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $2.72M derived: sum of 2 quarters · filed 2025-02-18 | $4.26M derived: sum of 3 quarters · filed 2025-02-18 | $6.66M 10-K · filed 2025-02-18 |
| 2024-09-30 | $1.01M 10-Q · filed 2024-11-05 | $2.55M derived: sum of 2 quarters · filed 2024-11-05 | $4.95M 10-Q · filed 2024-11-05 | $6.16M derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-06-30 | $1.54M 10-Q · filed 2024-07-30 | $3.94M 10-Q · filed 2024-07-30 | $5.15M derived: sum of 3 quarters · filed 2025-04-29 | $7.27M derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-03-31 | $2.40M 10-Q · filed 2025-04-29 | $3.60M derived: sum of 2 quarters · filed 2025-04-29 | $5.73M derived: sum of 3 quarters · filed 2025-04-29 | $8.80M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $3.33M derived: sum of 2 quarters · filed 2025-02-18 | $6.40M derived: sum of 3 quarters · filed 2025-02-18 | $11.09M 10-K · filed 2025-02-18 |
| 2023-09-30 | $2.13M 10-Q · filed 2024-11-05 | $5.20M derived: sum of 2 quarters · filed 2024-11-05 | $9.88M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $3.07M 10-Q · filed 2024-07-30 | $7.76M 10-Q · filed 2024-07-30 | ||
| 2022-12-31 | $4.52M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |